ArticleJournal of neuropathology and experimental neurology2026
Morroniside maintains mitochondrial homeostasis in microglia and mitigates neuroinflammation in experimental autoimmune encephalomyelitis.
Article in Journal of neuropathology and experimental neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Microglia-mediated neuroinflammation in the central nervous system is a hallmark of both multiple sclerosis (MS) and the animal model experimental autoimmune encephalomyelitis (EAE). Current immunosuppressive therapies for MS have limited efficacy and notable side effects. This study aimed to investigate mechanisms underlying anti-neuroinflammatory effects of morroniside, an iridoid glycoside derived from Cornus officinalis, which is used in Chinese herbal medicine. Morroniside treatment significantly attenuated lipopolysaccharide-induced alterations and mitochondrial dysfunction in BV2 microglia cells. In vivo, morroniside treatment improved clinical scores and ameliorated pathological findings and neurological deficits in a mouse EAE model. Mechanistic investigations revealed that morroniside activated the Nrf2/HO-1 signaling axis, promoted Nrf2 nuclear translocation and elevated HO-1 expression. This activation also upregulated p62, thereby enhancing LC3-II/PINK1/Parkin-mediated mitophagosome formation. The resultant mitophagy suppressed p65 phosphorylation leading to anti-inflammatory effects. Collectively, our findings suggest that morroniside ameliorates EAE by increasing anti-inflammatory microglial activation through upregulating the Nrf2/HO-1/p62 axis to mitigate mitochondrial oxidative stress and enhance mitophagy. These results identify morroniside as a promising therapeutic candidate for MS and emphasize the importance of the Nrf2-p62-mitophagy axis in resolving neuroinflammation and maintaining mitochondrial homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.